Literature DB >> 21490275

IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells.

Saori Furuta1, Yung-Ming Jeng, Longen Zhou, Lan Huang, Irene Kuhn, Mina J Bissell, Wen-Hwa Lee.   

Abstract

As cells differentiate into tissues, the microenvironment that surrounds these cells must cooperate so that properly organized, growth-controlled tissues are developed and maintained. We asked whether substances produced from this collaboration might thwart malignant cells if they arise in the vicinity of normal tissues. Here, we identified six factors secreted by nonmalignant mammary epithelial cells (MECs) differentiating in three-dimensional laminin-rich gels that exert cytotoxic activity on breast cancer cells. Among these, interleukin-25 (IL-25/IL-17E) had the highest anticancer activity without affecting nonmalignant MECs. Apoptotic activity of IL-25 was mediated by differential expression of its receptor, IL-25R, which was expressed in high amounts in tumors from patients with poor prognoses but was low in nonmalignant breast tissue. In response to IL-25, the IL-25R on the surface of breast cancer cells activated caspase-mediated apoptosis. Thus, the IL-25/IL-25R signaling pathway may serve as a new therapeutic target for advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490275      PMCID: PMC3199022          DOI: 10.1126/scitranslmed.3001374

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  29 in total

Review 1.  Autocrine and paracrine growth inhibitors of breast cancer cells.

Authors:  X L Bourhis; R A Toillon; B Boilly; H Hondermarck
Journal:  Breast Cancer Res Treat       Date:  2000-04       Impact factor: 4.872

2.  IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo.

Authors:  M M Fort; J Cheung; D Yen; J Li; S M Zurawski; S Lo; S Menon; T Clifford; B Hunte; R Lesley; T Muchamuel; S D Hurst; G Zurawski; M W Leach; D M Gorman; D M Rennick
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

3.  Mass spectrometric characterization of the affinity-purified human 26S proteasome complex.

Authors:  Xiaorong Wang; Chi-Fen Chen; Peter R Baker; Phang-lang Chen; Peter Kaiser; Lan Huang
Journal:  Biochemistry       Date:  2007-02-27       Impact factor: 3.162

4.  IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1.

Authors:  J Lee; W H Ho; M Maruoka; R T Corpuz; D T Baldwin; J S Foster; A D Goddard; D G Yansura; R L Vandlen; W I Wood; A L Gurney
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

Review 5.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

6.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini.

Authors:  S K Muthuswamy; D Li; S Lelievre; M J Bissell; J S Brugge
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

7.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Authors:  Richard M Neve; Koei Chin; Jane Fridlyand; Jennifer Yeh; Frederick L Baehner; Tea Fevr; Laura Clark; Nora Bayani; Jean-Philippe Coppe; Frances Tong; Terry Speed; Paul T Spellman; Sandy DeVries; Anna Lapuk; Nick J Wang; Wen-Lin Kuo; Jackie L Stilwell; Daniel Pinkel; Donna G Albertson; Frederic M Waldman; Frank McCormick; Robert B Dickson; Michael D Johnson; Marc Lippman; Stephen Ethier; Adi Gazdar; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

8.  Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production.

Authors:  Mee Rhan Kim; Raffi Manoukian; Richard Yeh; Scott M Silbiger; Dimitry M Danilenko; Sheila Scully; Jilin Sun; Margaret L DeRose; Marina Stolina; David Chang; Gwyneth Y Van; Kristie Clarkin; Hung Q Nguyen; Yan Bin Yu; Shuqian Jing; Giorgio Senaldi; Gary Elliott; Eugene S Medlock
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

9.  Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production.

Authors:  Sanjay Kumar; Charles R Hanning; Michael R Brigham-Burke; David J Rieman; Ruth Lehr; Sanjay Khandekar; Robert B Kirkpatrick; Gilbert F Scott; John C Lee; Frank J Lynch; Wentao Gao; Andrea Gambotto; Michael T Lotze
Journal:  Cytokine       Date:  2002-04-21       Impact factor: 3.861

10.  Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition.

Authors:  Thorarinn Gudjonsson; Lone Rønnov-Jessen; René Villadsen; Fritz Rank; Mina J Bissell; Ole William Petersen
Journal:  J Cell Sci       Date:  2002-01-01       Impact factor: 5.285

View more
  46 in total

1.  Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells.

Authors:  Zizhen Kang; Chenhui Wang; Jarod Zepp; Ling Wu; Kevin Sun; Junjie Zhao; Unni Chandrasekharan; Paul E DiCorleto; Bruce D Trapp; Richard M Ransohoff; Xiaoxia Li
Journal:  Nat Neurosci       Date:  2013-09-01       Impact factor: 24.884

2.  Diabetes induces IL-17A-Act1-FADD-dependent retinal endothelial cell death and capillary degeneration.

Authors:  Sarah I Lindstrom; Sigrun Sigurdardottir; Thomas E Zapadka; Jie Tang; Haitao Liu; Brooklyn E Taylor; Dawn G Smith; Chieh A Lee; John DeAngelis; Timothy S Kern; Patricia R Taylor
Journal:  J Diabetes Complications       Date:  2019-05-29       Impact factor: 2.852

Review 3.  IL-17 family: cytokines, receptors and signaling.

Authors:  Chunfang Gu; Ling Wu; Xiaoxia Li
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

4.  Lineage tracing and targeting of IL17RB+ tuft cell-like human colorectal cancer stem cells.

Authors:  Norihiro Goto; Akihisa Fukuda; Yuichi Yamaga; Takaaki Yoshikawa; Takahisa Maruno; Hisatsugu Maekawa; Susumu Inamoto; Kenji Kawada; Yoshiharu Sakai; Hiroyuki Miyoshi; Makoto Mark Taketo; Tsutomu Chiba; Hiroshi Seno
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-10       Impact factor: 11.205

Review 5.  The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity.

Authors:  Xinyang Song; Xiao He; Xiaoxia Li; Youcun Qian
Journal:  Cell Mol Immunol       Date:  2016-03-28       Impact factor: 11.530

6.  Interleukin-17B Antagonizes Interleukin-25-Mediated Mucosal Inflammation.

Authors:  Joseph M Reynolds; Young-Hee Lee; Yun Shi; Xiaohu Wang; Pornpimon Angkasekwinai; Kalyan C Nallaparaju; Stephanie Flaherty; Seon Hee Chang; Hiroshi Watarai; Chen Dong
Journal:  Immunity       Date:  2015-04-14       Impact factor: 31.745

7.  Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.

Authors:  Jia-Jia Li; Wei-Ling Chen; Jian-Yi Wang; Qian-Wen Hu; Zhen-Ping Sun; Shuai Zhang; Sheng Liu; Xiang-Hui Han
Journal:  Acta Pharmacol Sin       Date:  2017-04-17       Impact factor: 6.150

8.  RORα suppresses breast tumor invasion by inducing SEMA3F expression.

Authors:  Gaofeng Xiong; Chi Wang; B Mark Evers; Binhua P Zhou; Ren Xu
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

9.  IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis.

Authors:  Elisa Ferretti; Emma Di Carlo; Emanuela Ognio; Giulio Fraternali-Orcioni; Anna Corcione; Beatrice Belmonte; Jean Louis Ravetti; Claudio Tripodo; Domenico Ribatti; Vito Pistoia
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

10.  Peritumoral eosinophils predict recurrence in colorectal cancer.

Authors:  Lars Harbaum; Marion J Pollheimer; Peter Kornprat; Richard A Lindtner; Carsten Bokemeyer; Cord Langner
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.